Debt-to-equity in % of Checkpoint Therapeutics, Inc. from Q2 2017 to Q1 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Checkpoint Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q2 2017 to Q1 2025.
Checkpoint Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Mar 2025 was -313 %, a 119% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Checkpoint Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q1 2025	-313	-170	-119%	31 Mar 2025
Q4 2024	-159	-31	-24.2%	31 Dec 2024
Q3 2024	-155	-19.2	-14.2%	30 Sep 2024
Q2 2024	-143	+30.7	+17.6%	30 Jun 2024
Q1 2024	-143	+163	+53.3%	31 Mar 2024
Q4 2023	-128	-1.63K	-109%	31 Dec 2023
Q3 2023	-135	-307	-179%	30 Sep 2023
Q2 2023	-174	-256	-313%	30 Jun 2023
Q1 2023	-305	-351	-766%	31 Mar 2023
Q4 2022	1.5K	+1.47K	+5010%	31 Dec 2022
Q3 2022	172	+153	+808%	30 Sep 2022
Q2 2022	81.9	+65.4	+396%	30 Jun 2022
Q1 2022	45.8	+25.5	+125%	31 Mar 2022
Q4 2021	29.4	+1.83	+6.64%	31 Dec 2021
Q3 2021	18.9	-15	-44.3%	30 Sep 2021
Q2 2021	16.5	-37.9	-69.7%	30 Jun 2021
Q1 2021	20.3	-43.4	-68.1%	31 Mar 2021
Q4 2020	27.6	-54	-66.2%	31 Dec 2020
Q3 2020	33.9	-80.8	-70.5%	30 Sep 2020
Q2 2020	54.4	-24.8	-31.3%	30 Jun 2020
Q1 2020	63.7	+5.59	+9.62%	31 Mar 2020
Q4 2019	81.6	+39.2	+92.4%	31 Dec 2019
Q3 2019	115	+81.5	+245%	30 Sep 2019
Q2 2019	79.2	+48.5	+158%	30 Jun 2019
Q1 2019	58.1	+31.2	+116%	31 Mar 2019
Q4 2018	42.4	+19.1	+82.1%	31 Dec 2018
Q3 2018	33.2	+16.3	+96.2%	30 Sep 2018
Q2 2018	30.7	+17.1	+125%	30 Jun 2018
Q1 2018	26.9			31 Mar 2018
Q4 2017	23.3			31 Dec 2017
Q3 2017	16.9			30 Sep 2017
Q2 2017	13.6			30 Jun 2017

* An asterisk sign (*) next to the value indicates that the value is likely invalid.